New hope for kidney transplant patients: safer rejection prevention?
NCT ID NCT06365437
First seen Mar 16, 2026 · Last updated Jun 19, 2026 · Updated 17 times
Summary
This study tested a new drug called TCD601 (siplizumab) in 33 kidney transplant patients to see if it could safely prevent organ rejection. The drug was compared to a standard treatment (ATG). The trial was stopped early, so we have limited information, but the goal was to find a gentler option for transplant recipients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
-
Hospital Universitari de Bellvitge
Barcelona, 08907, Spain
-
Innsbruck Medical University
Innsbruck, A-6020, Austria
-
Karolinska University Hospital
Stockholm, Huddinge, 14157, Sweden
-
Sahlgrenska University Hospital
Gothenburg, 41345, Sweden
-
Skåne University Hospital
Malmö, 20502, Sweden
-
University of Vienna
Vienna, 1090, Austria
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TCD601 (siplizumab)
What this could lead to
If it works, this could point toward a safer way to prevent organ rejection after kidney transplant, reducing side effects compared to current treatments.
What could go wrong
This is an early, small Phase 2 trial that was terminated, so results are limited. The drug may not prove safer or more effective than standard therapy, and risks include infection and rejection.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.